A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray

Inclusion Criteria: Part 1: * Healthy male or female subjects aged 18 to 55 years old (inclusive); * Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females; body mass index (BMI) within the range of 18.5 to 28.0 kg/m2 (inclusive); * No clinically significant abnormalities at screening or baseline. Part 2: * Male or female patients aged 18 to 55 years old (inclusive); * Clinically confirmed diagnosis of chronic rhinosinusitis with or without nasal polyps; * Presence of the following symptoms for \>4 weeks before screening: nasal obstruction, mucous or mucopurulent rhinorrhea, facial pain/pressure, and reduced or lost sense of smell; * Modified Lund-Kennedy (MLK) score ≥ 2 in each nostril by nasal endoscopy; * Lund-Mackay score (LMK) ≥ 2 in each nostril by CT scan; * Nasal Construction Score (NCS) ≥ 2. Exclusion Criteria: Part 1: * Known hypersensitivity or contraindications to the study drug or its components; * History or current conditions that affect the safety or absorption of the investigational drug; * History of drug abuse or drug dependence; * Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer; * If female, is pregnant or lactating, or intends to become pregnant during the study period. Part 2: * Known hypersensitivity or contraindications to the study drug or its components; * Use of prohibited medications prior to screening and during the course of the study; History of drug abuse or drug dependence; * Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer; * If female, is pregnant or lactating, or intends to become pregnant during the study period.